Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.

Pfankuchen DB, Baltes F, Batool T, Li JP, Schlesinger M, Bendas G

Oncotarget 8 (40) 67553-67566 [2017-09-15; online 2017-06-28]

Low molecular weight heparin (LMWH), the guideline based drug for prophylaxis and treatment of cancer-associated thrombosis, was recently shown to sensitize cisplatin resistant A2780cis human ovarian cancer cells for cisplatin cytotoxicity upon 24 h pretreatment with 50 μg × mL

Affiliated researcher

PubMed 28978053

DOI 10.18632/oncotarget.18738

Crossref 10.18632/oncotarget.18738

pii: 18738
pmc: PMC5620193

Publications 9.5.0